PDCD1 and hepatocellular carcinoma: In addition, VEGFR-2 inhibition was associated with upregulation of IFN-γ and PD-L1 expression, and simultaneous blockade of PD-1 and VEGFR-2 in HCC can promote vascular normalization and enhance antitumor immune responses (24).